Latest Articles
The association between metabolic syndrome and incidence of endometrial cancer: a meta-analysis - Diabetology & Metabolic Syndrome
The association between metabolic syndrome and incidence of endometrial cancer: a meta-analysis Diabetology & Metabolic Syndrome
Published: Nov. 17, 2025, 6:01 p.m.
Patients with early Endometrial Cancer who don't undergo Hysterectomy have Higher Mortality: Study - Medical Dialogues
Patients with early Endometrial Cancer who don't undergo Hysterectomy have Higher Mortality: Study Medical Dialogues
Published: Nov. 16, 2025, 4:30 p.m.
Ane Gerda Zahl Eriksson: SENSOR-LIIFE - Advancing Exercise Research in Endometrial Cancer Survivor - Oncodaily
Ane Gerda Zahl Eriksson: SENSOR-LIIFE - Advancing Exercise Research in Endometrial Cancer Survivor Oncodaily
Published: Nov. 16, 2025, 9:57 a.m.
Endometrial Cancer Cure Rate: What Patients Need to Know in 2025 - Oncodaily
Endometrial Cancer Cure Rate: What Patients Need to Know in 2025 Oncodaily
Published: Nov. 16, 2025, 8:17 a.m.
FDA approves Promega’s OncoMate test to guide personalised treatment for endometrial cancer - Indian Pharma Post
FDA approves Promega’s OncoMate test to guide personalised treatment for endometrial cancer Indian Pharma Post
Published: Nov. 14, 2025, 3:26 p.m.
Metabolomics reveals the therapeutic efficacy of liposomal resvida in endometrial cancer through regulating autophagy-related gene expression - Cancer Cell International
Metabolomics reveals the therapeutic efficacy of liposomal resvida in endometrial cancer through regulating autophagy-related gene expression Cancer Cell International
Published: Nov. 14, 2025, 4:25 a.m.
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 - Quiver Quantitative
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 Quiver Quantitative
Published: Nov. 13, 2025, 9:25 p.m.
Insufficient Endometrial Biopsy Increases Cancer Risk - European Medical Journal
Insufficient Endometrial Biopsy Increases Cancer Risk European Medical Journal
Published: Nov. 13, 2025, 1:03 p.m.
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer - Voice Of HealthCare
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer Voice Of HealthCare
Published: Nov. 13, 2025, 6:17 a.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어
Published: Nov. 13, 2025, 5:50 a.m.
Link copied to clipboard!